EVFM (Evofem Biosciences) Total Inventories: $1.89 Mil (As of Mar. 2026)


What is Evofem Biosciences Total Inventories?

Evofem Biosciences EVFM -0.06% Total Inventories is $1.89 Mil as of Mar. 2026. The stock has 5 warning signs investors should review.

Evofem Biosciences's total inventories for the quarter that ended in Mar. 2026 was $1.89 Mil. Evofem Biosciences's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was $1.51 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Evofem Biosciences's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was $-0.62.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Evofem Biosciences's Days Inventory for the three months ended in Mar. 2026 was 335.96.

Inventory Turnover measures how fast the company turns over its inventory within a year. Evofem Biosciences's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.27.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Evofem Biosciences's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 1.68.

Evofem Biosciences  (OTCPK:EVFM) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Evofem Biosciences's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is

Net-Net Working Capital Per Share (Q: Mar. 2026 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(1.491+0.75 * 0.56+0.5 * 1.89-85.072
-0-0)/132.530
=-0.62

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Evofem Biosciences's Days Inventory for the three months ended in Mar. 2026 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2026 )/Cost of Goods Sold (Q: Mar. 2026 )*Days in Period
=1.5095/0.41*365 / 4
=335.96

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Evofem Biosciences's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2026 ) / Average Total Inventories (Q: Mar. 2026 )
=0.41 / 1.5095
=0.27

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Evofem Biosciences's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=1.5095 / 0.899
=1.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Evofem Biosciences Total Inventories Related Terms

Evofem Biosciences Total Inventories Historical Data

* Premium members only.

The historical data trend for Evofem Biosciences's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evofem Biosciences Total Inventories Chart

Evofem Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.67 5.38 1.70 1.58 1.13

Evofem Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.26 1.91 1.68 1.13 1.89

Evofem Biosciences Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Frequently Asked Questions Learn more about Total Inventories →
What does a Total Inventories of $1.89 Mil mean?
Evofem Biosciences (EVFM) has a Total Inventories of $1.89 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Evofem Biosciences and its competitors.
Is Evofem Biosciences' Total Inventories too high?
Evofem Biosciences' current Total Inventories is $1.89 Mil.
How does Evofem Biosciences' Total Inventories compare to PTIX and ATXI?
Evofem Biosciences' Total Inventories of $1.89 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Evofem Biosciences and its competitors. Evofem Biosciences's current Total Inventories is $1.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evofem Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Evofem Biosciences (EVFM) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 12.8% below its estimated fair value. The current Total Inventories is $1.89 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Evofem Biosciences (EVFM), the current Total Inventories is $1.89 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evofem Biosciences Business Description

Address 7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.